Management of Hypertriglyceridemia and Diabetes

Initial Therapy

The American College of Cardiology recommends starting fenofibrate 160 mg daily with meals as first-line therapy for severe hypertriglyceridemia, along with extreme dietary fat restriction (<5% of total calories) until triglycerides are <1000 mg/dL, and eliminating added sugars and alcohol completely 1
The American College of Cardiology also suggests starting SGLT2 inhibitor to improve glycemic control, reduce cardiovascular risk, and provide renal protection, and considering adding GLP-1 receptor agonist for additional glycemic control and weight reduction benefits 2

The American Academy of Family Physicians and the American College of Physicians recommend targeting HbA1c of ≤7.0% and monitoring blood glucose levels frequently, with the American College of Physicians also recommending starting ACE inhibitor or ARB for microalbuminuria, with a target blood pressure <130/80 mmHg 3, 4

The American College of Cardiology recommends adding high-intensity statin after triglycerides are <500 mg/dL, with a target LDL-C <100 mg/dL, and considering adding ezetimibe if LDL goal not achieved with statin alone, while avoiding combination of statins with gemfibrozil due to increased risk of myositis 1, 4, 5
The American College of Cardiology prioritizes triglyceride control first before aggressive LDL management when triglycerides >500 mg/dL due to pancreatitis risk 1, 5

The American Academy of Family Physicians recommends implementing comprehensive dietary changes, including a very low-fat diet (<5% of calories from fat) until triglycerides <500 mg/dL, and transitioning to a heart-healthy diet with <30% calories from fat, <7% from saturated fat, and limiting sodium to <1500 mg/day, with an emphasis on vegetables, legumes, fatty fish, fiber-rich whole grains, and nuts 1, 3
Reducing added sugars and fructose can contribute an additional 10-20% reduction in triglyceride levels, as suggested by the American Heart Association, and carbohydrate restriction, specifically very low-carbohydrate diets (<10% of calories from carbohydrates), can reduce triglycerides by 24 mg/dL 6, 1
Increasing dietary fiber to more than 10g/day is essential for managing severe hypertriglyceridemia, as recommended by the American College of Cardiology and the Academy of Nutrition and Dietetics, and at least 150 minutes per week of moderate-intensity or 75 minutes of vigorous aerobic activity can help manage triglycerides 1, 7

Fibrates, such as fenofibrate 160 mg daily with meals, are recommended as first-line therapy for severe hypertriglyceridemia by the American Diabetes Association and the American College of Cardiology, and omega-3 fatty acids (4 g/day) can be used alone or in combination with fibrates for the treatment of severe hypertriglyceridemia 8, 9
Statins may be considered if concurrent elevated LDL-C exists, but combination therapy with fibrates should be approached with caution due to the increased risk of myopathy, as advised by the American Diabetes Association and the American College of Cardiology, and niacin can be used as a second-line option, but with caution in patients with diabetes 8, 9, 10, 5

IV insulin therapy (with or without heparin) is the first-line treatment for triglycerides >1000 mg/dL despite 48-hour fasting, particularly effective in patients with hyperglycemia, and plasmapheresis should be considered when triglycerides remain significantly elevated despite insulin therapy, as recommended by the Clinical Nutrition guidelines 11, 7
Early enteral nutrition (within 24-72 hours from admission) is recommended, and patients with hypertriglyceridemia-induced pancreatitis should begin oral feeding when pain has ceased, amylase and lipase values are decreasing, and there are no contraindications to enteral nutrition, typically within 24-72 hours after IV insulin initiation, as stated in Clinical Nutrition guidelines 11, 12
Parenteral nutrition should only be used when enteral nutrition is not tolerated or impossible, with a diet composition high in carbohydrates and protein, low in fat (<30% of total energy), as recommended by Clinical Nutrition guidelines and the American Society for Parenteral and Enteral Nutrition 7, 11

Hypertriglyceridemia is classified based on fasting serum triglyceride levels, with categories including normal (<150 mg/dL), mild to moderate (150-499 mg/dL), severe (500-999 mg/dL), and very severe (≥1000 mg/dL) 13, 1
Triglyceride levels approaching or exceeding 1000 mg/dL pose a significant risk of pancreatitis, as noted by the American Heart Association, and monitoring triglyceride levels every 4-8 hours for the first 24 hours after acute treatment, every 24 hours until stable, and every 4-8 weeks until stabilized, then every 3 months, with a target triglyceride level of <500 mg/dL to reduce pancreatitis risk, as recommended by the American College of Cardiology 9, 8, 6
Evaluate renal function before initiation of fenofibrate, within 3 months after starting, and every 6 months thereafter, and avoid use in severe renal impairment, as recommended by the American College of Cardiology and the National Kidney Foundation 7, 11, 14

The American Diabetes Association recommends administering subcutaneous basal insulin 2-4 hours before discontinuing IV insulin infusion, with a dose calculated at 60-80% of the daily IV insulin infusion rate, and continue dextrose infusion as needed to maintain euglycemia during the transition 15, 16, 17